

[La Belle Forme @ Glasgow Day Surgery Centre]: SUMMARY OF ACTION PLAN TO ACHIEVE FULL COMPLIANCE WITH PART 4 OF THE PRIVATE HEALTHCARE MARKET INVESTIGATION ORDER 2014

| Measure | Milestones in | Milestones in | Milestones in | Milestones in | Milestones in | Milestones in | Date of full |
|----------------|-----------------|---------------|---------------|---------------|---------------|---------------|--------------|
| | February 2024 | March 2024 | [Month 3] | [Month 4] | [Month 5] | [Month 6] | compliance |
| Volume | Data for period | | | | | | February |
| | from Oct 2022 | | | | | | 2024 |
| | to Sept 2023 | | | | | | |
| | submitted. We | | | | | | |
| | continue to | | | | | | |
| | monitor to | | | | | | |
| | ensure data is | | | | | | |
| | submitted in | | | | | | |
| | time. | | | | | | |
| Length of stay | Data for period | | | | | | February |
| | from Oct 2022 | | | | | | 2024 |
| | to Sept 2023 | | | | | | |
| | submitted. We | | | | | | |
| | continue to | | | | | | |
| | monitor to | | | | | | |
| | ensure data is | | | | | | |
| | submitted in | | | | | | |
| | time. | | | | | | |

| Adverse events | | Training to be | | | March 2024 |
|-------------------------|------------------|----------------|--|--|------------|
| | | organised and | | | |
| | | data to be | | | |
| | | submitted on | | | |
| | | ongoing basis | | | |
| Patient feedback | | Training to be | | | March 2024 |
| | | organised and | | | |
| | | data to be | | | |
| | | submitted on | | | |
| | | ongoing basis | | | |
| Health outcome measures | This is not | | | | February |
| | applicable to | | | | 2024 |
| | our site as we | | | | |
| | do not carry out | | | | |
| | any procedures | | | | |
| | which require | | | | |
| | PROMs data | | | | |
| Clinical coding | Coding Errors | | | | February |
| | have been | | | | 2024 |
| | addressed with | | | | |
| | a dedicated | | | | |
| | team put in | | | | |
| | place to ensure | | | | |
| | that errors | | | | |
| | returned are | | | | |
| | minimal. | | | | |